Item 7. Management's Discussion and Analysis of Financial Condition and 
Results of Operations 
167
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
177
Item 8. 
Financial Statements
 and Supplementary Data
179
Item 9. Changes in and Disagreements with Accountants on Accounting and 
Financial Disclosures 
220
Item 9A. Controls and Procedures 
220
Item 9B. Other Information
222
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
222
PART

03
Item 10. Directors, Executive Officers and Corporate Governance
223
Item 11. Executive Compensation 
223
Item 12. Security Ownership of Certain Beneficial Owner and Management and 
Related Stockholder Matters
223
Item 13. Certain Relationships and Related Transactions and Director 
Independence 
223
Item 14. Principal Accounting Fees and Services
223
PART

04
Item 15. 
Exhibits
 and Financial Statement Schedules
224
Item 16. Form 10-K Summary
227
Signatures
228
3
Table of Contents
PART I
Risk Factor Summary
Below is a summary of the principal factors that make an investment in the common stock of Recursion Pharmaceuticals, Inc. (Recursion, the Company, we, us, or our) risky or speculative. This summary does not address all of the risks we face. Additional discussion of the risks summarized below, and other risks that we face, can be found in the section titled â€œ